Cerevel remains committed to developing treatment options for people living with #schizophrenia through our ongoing EMPOWER clinical trial program. Thanks, Nasdaq for joining us in support yesterday! empowerstudies.com
Cerevel Therapeutics’ Post
More Relevant Posts
-
💡 🌱 On 4/20 (#IYKYK), we were joined by Dr. Aaron Boster, neurologist & MS specialist, who diligently answered a variety of questions related to the use of medical marijuana in the setting of neurological conditions. We are so grateful to Dr. Boster for his knowledge, openness, expertise and advocacy for this important topic as well as helping us to continue cultivating a safe space / zero-judgment zone for patients and their loved ones. Watch this insightful webinar in its entirety: https://lnkd.in/ew3664FY
To view or add a comment, sign in
-
PurMinds is charting an ambitious course with a dynamic two-pronged strategy for success in neurological care and value for our investors: Long-term Vision: We're committed to creating substantial value by advancing a clinical pipeline. Our goal? Confronting neurological disorders with Novel Chemical Entities and innovative therapies, paving the way for a brighter future. Short- and Medium-Term Focus: Leveraging our expertise in psychedelic compound supply for global trials, and licensing our our proprietary formulation technology platform via a US joint venture, prioritizing short and medium-term revenue growth. Explore the details at PurMinds.com 🌐 #NeurologicalInnovation #LeadingTheWay #InvestingNews
To view or add a comment, sign in
-
A new era for @KinesysConsulting! Joining @Clinigen strengthens our capabilities and allows us to make a significant contribution to accelerating the development of life-saving therapies. #RegulatoryAffairs #PatientAccess #DrugLifecycle
To view or add a comment, sign in
-
This Multiple Sclerosis Awareness Month 🧡 , join Vivpro Corp as we illuminate the landscape of regulatory intelligence in this critical area. With our #RIA platform, you can: 1️⃣ Effortlessly search through a multitude of approved products and clinical trials with one intuitive workflow. 2️⃣ Search any indication to discover products that have received "expedited pathways." 3️⃣ Quickly replicate a competitor's Clinical Development Plan and see which trials may have led to approval with RIA's CDP module! 4️⃣ RIA offers quick access to vital Clinical Trials Data. Stay at the forefront of the ever-evolving drug development landscape. ➡ 📞 Schedule a call with us to learn more. https://vivpro.ai/contact #MS #MultipleSclerosis #MSResearch #RegulatoryIntelligence #DrugDevelopment #WisdomWednesday #Vivpro #MorePowerToYou
To view or add a comment, sign in
-
Today, on #Juneteenth, we don't just celebrate liberation – we ignite it. At Molekule Consulting LLC, we channel the unyielding spirit of those who fought for freedom into our relentless pursuit of groundbreaking biopharma solutions. Just as the echoes of Juneteenth reverberate through history, our impact echoes through the lives transformed by the medicines we help bring to the world. We shatter barriers, defy limitations, and rewrite the rules of what's possible in healthcare. But our work is far from finished. The struggle for health equity is a marathon, not a sprint. We stand shoulder-to-shoulder with those who continue to fight for a world where every life is valued, every voice is heard, and every person has the opportunity to thrive. On this Juneteenth, we don't just honor the past – we forge the future. Join us as we revolutionize healthcare, empower communities, and create a legacy of progress that burns as brightly as the Juneteenth sun. #DiversityInBiopharma #Innovation #Pharma #HealthEquity
To view or add a comment, sign in
-
We are thrilled to share that PurMinds Neuropharma's CEO, Janet Qi, has been featured in Clinical Leader’s latest article, "The Best Advice I Ever Got: On The Job" by Abby Proch. Janet’s invaluable insights on navigating the complexities of psychedelic clinical trials are a testament to our commitment to innovation and excellence in the field. Check out the full article to learn more about her advice on partnering with experienced CROs and leveraging their expertise to drive transformative therapies forward. Link in comments! #ClinicalResearch #PurMindsNeuropharma #PsychedelicResearch #ClinicalLeader #ClinicalTrialsDay2024 #InnovationInPharma
To view or add a comment, sign in
-
Executive Director, Blue Spoon Consulting® / The Global Leader in Positioning Strategy at a System Level
23andMe CEO Anne Wojcicki said she’s “open to all ideas” in addressing investor confusion and turning around a disappointing start to the genomic pioneer’s life as a public company. Even as the J.P. Morgan Healthcare Conference brought a burst of optimism to start 2024, stoked by a rallying biotech market and improving macroeconomic climate, 23andMe’s stock dropped another 14% last week. The South San Francisco-based biotech, best known for selling DNA sequencing kits to millions of people and now also developing its own drugs, has seen its stock price fall over 90% since going public in June 2021. It’s taken the company’s valuation from $3.5 billion at its market debut to roughly $307 million. via Andrew Dunn @ Endpoints News ********* Here's an idea: Position your business for the 'creator economy' Give the more than 14 million people who provided data to 23andMe a cut of future earnings and sales from all new markets, products and technologies derived from their data. #Provenance and data equity -- the origin of things and the fair value of the "data" used to develop those things -- are emerging strategic themes that will/can reshape economics in healthcare. Just ask the brand teams for the first 10 drugs selected by the Centers for Medicare & Medicaid Services for negotiating through the IRA. Better yet, just ask J.P. Morgan attendee Thermo Fisher Scientific. They were sued successfully by the family of Henrietta Lacks, a Black woman who had cells taken from her and used for research without consent more than 70 years ago. (Thermo Fisher Scientific earned billions from products and services derived from her cells.) Terms were not disclosed, but the legal team for the family is promising more. You can either get in front of this emerging story and shape it to your advantage, or sit back and become a victim of it, let it wash over you. Lost in the euphoria of all things possible with the technical potential of generative artificial intelligence is this: When it comes to large-scale change -- the 'next hundred billion' in growth, say, or entirely new economic systems -- the sequence should be economic innovation first, technology innovation second. Call it the Big Strategic Reordering. cc: Epic, Cerner Corporation, Google, OpenAI, Meta, Truveta, PhRMA and many, many more, whose commercial models are derived from data provided by customers/consumers/patients. cc: Blue Spoon Consulting, the global leader in positioning strategy at a system level cc: Reza Afkhami, Neal Mohan, Roelof Botha, Patrick S. Chung, Valerie Montgomery Rice, Peter Taylor, Sandra R. Hernández, M.D. #TheVisionThing https://lnkd.in/eu5uwFdY
To view or add a comment, sign in
-
Boost classroom focus with these do’s and don’ts! Create structure, use visual aids, and incorporate breaks. Avoid lengthy tasks and distractions. Triumph Therapeutics is here to help with personalized strategies. #OccupationalTherapy #Focus #ClassroomTips #TriumphTherapeutics
To view or add a comment, sign in
-
Your voice matters and can make a difference in improving #lupusresearch. The more people involved in the clinical trial process, the closer we are to a cure for #lupus. Learn how you can get involved this #LupusAwarenessMonth: https://lnkd.in/esmUVvvw #ManyOneCan
To view or add a comment, sign in
-
#Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury. This innovative product, currently undergoing clinical trial application in Europe, holds the promise of potentially making an impact on the lives of countless individuals and their families. Acute spinal cord injuries are life-changing events, and TZ-161 could be a ray of hope for those in need. The dedication and hard work of the Technophage team, in collaboration with the CRO team from VectorB2B - Drug Development alongside medical professionals and researchers, are paving the way for this remarkable development. Let's keep our fingers crossed and support this endeavor by spreading the word about TZ-161 and the positive impact it can have on patients' lives. #spinalcordinjury #technophage #partnerships #clinicaltrials
To view or add a comment, sign in
26,355 followers